Les publications HAL IRSET

2023

564 publication(s):

Note: when necessary, only the first 5 authors are displayed.

Workshop/conference papers

: 501 -
: P-87 Are asbestos and strong inorganic acid mists the only occupational exposures that increase laryngeal cancer risk in the construction industry?
: Christine Barul, Kendya Gene, Danièle Luce
: 29th International Symposium on Epidemiology in Occupational Health (EPICOH 2023), Mar 2023, Mumbai, India.
: DOI : https://doi.org/10.1136/oem-2023-epicoh.144

: 502 -
: Stereotactic reirradiation for local prostate cancer recurrence: Mono-institutional experience of 108 patients.
: Manon Baty, Joel Castelli, Khemara Gnep, Nolwenn Delaby, Romain Mathieu et al.
: Stereotactic reirradiation for local prostate cancer recurrence: Mono-institutional experience of 108 patients. Genitourinary Cancers Symposium, Feb 2023, San Francisco, United States.
: DOI : https://doi.org/10.1200/JCO.2023.41.6_suppl.365

: 503 -
: Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance data report
: K. Bihan, L. Lipszyc, F. Lemaitre, A. Dautriche, S Fedrizzi et al.
: Annual Meeting of French Society of Pharmacology and Therapeutics, Jun 2023, Limoges, France.

: 504 -
: P-202 Evaluation de l[StQuote]efficacité des transfusions des concentrés plaquettaires traités par Amotosalen/UVA en chirurgie cardiaque
: Belkacem Bouali, Ayoub Rezzaoui, Hind Hamzeh-Cognasse, Anne-Claire Duchez, Nesrine Tebbeb et al.
: XXXIe Congrès de la Société Française de Transfusion Sanguine (SFTS), Nov 2023, Toulouse, France. pp.S138-S139,
: DOI : https://doi.org/10.1016/j.tracli.2023.09.247

: 505 -
: Pharmacokinetic interactions between abiraterone or enzalutamide, and antithrombotic drugs: A systematic review
: F. Boujonnier, F. Lemaitre, L. M. Scailteux
: Annual Meeting of French Society of Pharmacology and Therapeutics, Jun 2023, Limoges, France.

: 506 -
: Invasive Fungal Infections after CAR T-Cell Therapy for B-Cell Lymphoma: A Study from the French Descart Registry
: Amélie Bouvier, Amandine Durand, Nicolas Gower, Cristina Castilla-Llorente, Arnaud Campidelli et al.
: 65th ASH Annual Meeting, Dec 2023, San Diego, United States. pp.2140,
: DOI : https://doi.org/10.1182/blood-2023-185632

: 507 -
: Pharmacokinetics-pharmacodynamic study of subcutaneous infusion of daptomycin in healthy volunteers
: M. C Verdier, C. Maurille, C Creveuil, J. -J. Parienti, J. Michon et al.
: Annual Meeting of French Society of Pharmacology and Therapeutics, Jun 2023, Limoges, France. pp.39-40,
: DOI : https://doi.org/10.1111/fcp.12905

: 508 -
: Meta-analysis of phase I dose-finding studies: Application for protein kinase inhibitors developed in oncology
: Laura Caquelin, P. Badra, Moreno Ursino, Bruno Laviolle, Clara Locher et al.
: EPICLIN 2023 17e Conférence francophone d’Épidémiologie Clinique - 30e Journées des statisticiens des Centres de Lutte contre le Cancer, May 2023, Villers-lès-Nancy, France.
: DOI : https://doi.org/10.1016/j.respe.2023.101816

: 509 -
: Baseline circulating soluble factors as predictors of immune-related adverse events (irAEs) in patients (pts) with metastatic clear cell renal carcinoma (mRCC) treated with nivolumab: A translational NIVOREN GETUG-AFU 26 study.
: Lucia Carril-Ajuria, Marie Naigeon, Cecile Dalban, Aude Desnoyer, Nathalie Rioux-Leclercq et al.
: Baseline circulating soluble factors as predictors of immune-related adverse events (irAEs) in patients (pts) with metastatic clear cell renal carcinoma (mRCC) treated with nivolumab: A translational NIVOREN GETUG-AFU 26 study. Genitourinary Cancers Symposium, Feb 2023, San Francisco, United States.
: DOI : https://doi.org/10.1200/JCO.2023.41.6_suppl.724

: 510 -
: FRENCH REAL-WORD DATA ON RIX-FP PROPHYLAXIS USE IN PATIENTS WITH HAEMOPHILIA B
: S. Castet, F Volot, A. Fournel, D. Desprez, A. Hassoun et al.
: 16th Annual Congress of European Association for Haemophilia and Allied Disorders 2023, Feb 2023, Manchester, United Kingdom. pp.64.